Zurcher Kantonalbank Zurich Cantonalbank Purchases 5,746 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 80.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,861 shares of the company’s stock after buying an additional 5,746 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Verve Therapeutics were worth $179,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Verve Therapeutics by 5.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 16,479 shares of the company’s stock valued at $219,000 after acquiring an additional 871 shares in the last quarter. Arizona State Retirement System grew its position in shares of Verve Therapeutics by 9.3% during the 3rd quarter. Arizona State Retirement System now owns 12,343 shares of the company’s stock worth $164,000 after purchasing an additional 1,054 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Verve Therapeutics by 10.8% during the third quarter. Teacher Retirement System of Texas now owns 12,058 shares of the company’s stock worth $160,000 after purchasing an additional 1,174 shares during the period. E Fund Management Co. Ltd. raised its position in shares of Verve Therapeutics by 11.6% in the third quarter. E Fund Management Co. Ltd. now owns 14,397 shares of the company’s stock valued at $191,000 after buying an additional 1,499 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Verve Therapeutics by 18.0% in the third quarter. Principal Financial Group Inc. now owns 16,847 shares of the company’s stock valued at $223,000 after buying an additional 2,566 shares during the period. Institutional investors and hedge funds own 97.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on VERV. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Verve Therapeutics in a research report on Wednesday, February 28th. HC Wainwright assumed coverage on shares of Verve Therapeutics in a report on Monday, April 8th. They set a “buy” rating and a $15.00 price target for the company. Finally, Stifel Nicolaus decreased their price objective on shares of Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Verve Therapeutics Price Performance

NASDAQ:VERV opened at $6.16 on Wednesday. Verve Therapeutics, Inc. has a one year low of $5.84 and a one year high of $21.42. The company has a market cap of $516.95 million, a PE ratio of -1.97 and a beta of 1.94. The firm has a 50-day moving average of $10.78 and a 200-day moving average of $11.95.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.14. The business had revenue of $5.14 million for the quarter, compared to analysts’ expectations of $3.95 million. Verve Therapeutics had a negative return on equity of 39.33% and a negative net margin of 1,701.70%. On average, equities research analysts expect that Verve Therapeutics, Inc. will post -2.92 earnings per share for the current fiscal year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.